<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00537563</url>
  </required_header>
  <id_info>
    <org_study_id>HMR3647A_4017</org_study_id>
    <nct_id>NCT00537563</nct_id>
  </id_info>
  <brief_title>AMS VS MOXI Ketek vs Avelox in AMS</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Clinical efficacy between telithromycin and moxifloxacin at the post-therapy/test of cure&#xD;
      visit, and to assess the safety of telithromycin given once daily for 5 days vs moxifloxacin&#xD;
      given once daily for 10 days in the treatment of subjects with AMS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <completion_date type="Actual">September 2003</completion_date>
  <primary_completion_date type="Actual">September 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To demonstrate equivalence in clinical efficacy between telithromycin and moxifloxacin at the post-therapy/test of cure (TOC) visit.</measure>
    <time_frame>Days 17 to 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the safety of telithromycin given once daily for 5 days vs moxifloxacin given once daily for 10 days in the treatment of subjects with AMS.</measure>
  </secondary_outcome>
  <enrollment type="Actual">351</enrollment>
  <condition>Maxillary Sinusitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telithromycin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult subjects, aged 18 years or older, AMS diagnosed (clinically and radiologically)&#xD;
             who were willing to undergo rhinoscopic aspiration or deep nasal swab at the&#xD;
             baseline/pre-therapy visit. Female subjects of childbearing potential were required to&#xD;
             have a negative pregnancy test before undergoing any study procedure and to use an&#xD;
             accepted contraceptive method during the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who were breast-feeding or pregnant, as demonstrated by serum or urine pregnancy&#xD;
             tests carried out before exposure to study medication or the start of any study&#xD;
             procedure that could pose a risk to the fetus;&#xD;
&#xD;
          -  Subjects with a history of recurrent sinusitis (defined as more than 3 episodes of&#xD;
             sinusitis that required antibiotic therapy in the preceding 12 months);&#xD;
&#xD;
          -  Subjects with a history of chronic sinusitis (defined as symptoms lasting greater than&#xD;
             28 days);&#xD;
&#xD;
          -  Subjects with sphenoidal sinusitis involvement that required treatment other than oral&#xD;
             antibiotics;&#xD;
&#xD;
          -  Subjects with nosocomial-acquired sinusitis within 2 weeks (eg, hospitalization or&#xD;
             nonambulatory, institutional confinement, including nursing homes);&#xD;
&#xD;
          -  Subjects with any concomitant medication [including functionally significant, major&#xD;
             obstructive anatomical lesions likely to impair resolution of infection (eg, nasal&#xD;
             polyps extending past the middle turbinate, tumor, or severe septal deviation)], such&#xD;
             as: asthma, cystic fibrosis, immotile cilia syndrome, prior nasopharyngeal or sinus&#xD;
             surgery, sinus polyps, clinically relevant cardiovascular (eg, congestive heart&#xD;
             failure), neurologic, endocrine, or other major systemic disease that could have made&#xD;
             implementation of the protocol or interpretation of the study results difficult;&#xD;
&#xD;
          -  Subjects with a need for immediate surgery for maxillary sinusitis;&#xD;
&#xD;
          -  Subjects who used nasal, nasogastric, or nasotracheal catheters;&#xD;
&#xD;
          -  Subjects with previous sinus surgery within the past 6 months or sinus lavage within&#xD;
             the past 7 days;&#xD;
&#xD;
          -  Subject who were long-term (&gt; than or = to 4 weeks) users of nasal decongestants like&#xD;
             oxymetazoline 0.05%;&#xD;
&#xD;
          -  Subjects with suspected nonbacterial infections;&#xD;
&#xD;
          -  Subjects with a concomitant odontological infection that would require antibiotic&#xD;
             therapy or surgery;&#xD;
&#xD;
          -  Subjects with unknown or suspected hypersensitivity to, or a known or suspected&#xD;
             serious adverse reaction to either study medication, any fluoroquinolone, or any&#xD;
             macrolide antibiotic;&#xD;
&#xD;
          -  Subjects who would likely have required on-study treatment with drugs known to have&#xD;
             contraindicated drug interactions with either study medication and/or macrolides or&#xD;
             fluoroquinolones in general, including, but not limited to: ergot alkaloid&#xD;
             derivatives, cholinesterase inhibitors (eg, tacrine, donepezil, physostigmine)&#xD;
             ketamine, carbamazepine, St John's Wort, Class IA (eg, quinidine, procainamide), or&#xD;
             Class III antiarrhythmic agents (eg, amiodarone, sotalol);&#xD;
&#xD;
          -  Subjects who required anticoagulant therapy (eg, warfarin);&#xD;
&#xD;
          -  Subjects who received treatment with other systemic antibiotics (oral or parenteral)&#xD;
             within 14 days prior to study enrollment;&#xD;
&#xD;
          -  Subject who received moxifloxacin or another fluoroquinolone antibiotic for this&#xD;
             infectious episode;&#xD;
&#xD;
          -  Likelihood of required treatment during the study period with drugs not permitted by&#xD;
             the protocol;&#xD;
&#xD;
          -  Treatment with any investigational product in the last 1 month prior to study entry;&#xD;
&#xD;
          -  Subjects with a progressively fatal disease; life expectancy &lt;less than or = to 3&#xD;
             months;&#xD;
&#xD;
          -  Clinically relevant cardiovascular, hepatic, neurologic, endocrine, or other major&#xD;
             systemic disease making implementation of the protocol or interpretation of the study&#xD;
             results difficult;&#xD;
&#xD;
          -  History of drug or alcohol abuse;&#xD;
&#xD;
          -  Impaired hepatic function [as shown by previous clinical laboratory values of AST&#xD;
             (SGOT) and/or ALT (SGPT) &gt; than or = to 3 times the upper limit of reference range,&#xD;
             total bilirubin &gt; than 2 times the upper limit of reference range (except for&#xD;
             Gilbert's disease), encephalopathy, etc];&#xD;
&#xD;
          -  Impaired renal function [as shown by previous clinical laboratory values of creatinine&#xD;
             clearance &lt; than or = to 30 mL/min (&lt; than or = to 0.50 mL/sec), serum creatinine &gt;&#xD;
             than or = to 2.0 mg/dl (&gt; than or = to 176 micromol/L), etc]. Creatinine clearance may&#xD;
             have been estimated by formula or by nomogram;&#xD;
&#xD;
          -  Immunocompromised subjects, such as subjects with HIV infection and who had either an&#xD;
             AIDS-defining condition (eg, Kaposi's sarcoma and Pneumocystis carinii pneumonia), or&#xD;
             a CD4 + T-lymphocyte count of &lt; 200/mm3). A complete list is provided in Appendix 3 of&#xD;
             the clinical study protocol (see @@Appendix A.1.1).&#xD;
&#xD;
          -  subjects with neutropenia (&lt;1500 neutrophils/mm3) not attributable to the acute&#xD;
             infectious disease&#xD;
&#xD;
          -  subjects with metastatic or hematological malignancy&#xD;
&#xD;
          -  splenectomised subjects with known hyposplenia or asplenia&#xD;
&#xD;
          -  subjects with known IgG deficiency&#xD;
&#xD;
          -  Subject with known long QT syndrome or familiar history of long QT syndrome (if no&#xD;
             previous ECG has invalidated this risk factor), or personal history of coronary&#xD;
             disease, ventricular arrhythmia, bradycardia &lt; 50 beats/min, or known uncorrected&#xD;
             hypokalemia or hypomagnesemia, or who were treated with concomitant medication known&#xD;
             to prolong QT interval (eg, cisapride, pimozide, astemizaole, terfenadine, or potent&#xD;
             CYP3A4 inhibitors, such as: protease inhibitors, ketoconazole);&#xD;
&#xD;
          -  Mental condition that rendered the subject unable to understand the nature, scope, and&#xD;
             possible consequences of the study;&#xD;
&#xD;
          -  Subjects diagnosed with myasthenia gravis (ie, Protocol Amendment No. 1);&#xD;
&#xD;
          -  Subjects unlikely to comply with the protocol (eg, uncooperative attitude, inability&#xD;
             to return for follow-up visit, and unlikely to complete the study);&#xD;
&#xD;
          -  Subjects without a permanent residential address or home telephone number;&#xD;
&#xD;
          -  Any waiver of these inclusion/exclusion criteria was to be approved by the&#xD;
             investigator and Aventis on a case-by-case basis, prior to study enrollment. This was&#xD;
             to be documented by both the investigator and Aventis; or&#xD;
&#xD;
          -  No subject was allowed to enroll in this study more than once.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>September 28, 2007</study_first_submitted>
  <study_first_submitted_qc>September 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2007</study_first_posted>
  <last_update_submitted>February 15, 2012</last_update_submitted>
  <last_update_submitted_qc>February 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
    <mesh_term>Maxillary Sinusitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

